1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. Company
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
144.27 USD   +0.71%
06/25Pfizer says tweaked COVID-19 shots boost omicron protection
AQ
06/24INSIDER SELL : Moderna
MT
06/24Moderna COVID-19 shots now an option for older kids in US
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:

- revenue from product sales (95.7%) ;

- revenues from grants (4%);

- revenues from collaboration agreements (0.3%).

At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.

Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Number of employees : 2 700 people.
Sales per Business
20202021Delta
mRNA Medicines803.40100%18 471.00100% +2199.12%
USD in Million
Sales per region
20202021Delta
Europe--6 846.0037.1%-
United States764.5395.2%6 177.0033.4% +707.95%
Rest of World38.874.8%5 448.0029.5% +13917.39%
USD in Million
Managers
Name Title Age Since
Stéphane Bancel Chief Executive Officer & Director 48 2011
Stephen Hoge President 45 2015
David Meline Chief Financial Officer 63 2022
Juan Andres Chief Technical Operations & Quality Officer 56 2017
Paul Burton Chief Medical Officer 52 2021
Lavina A. Talukdar Senior Vice President & Head-Investor Relations - 2019
Shannon Klinger Secretary & Chief Legal Officer 50 2021
Marcello Damiani Chief Digital & Operational Excellence Officer 51 2018
Melanie Ivarsson, Dr. Chief Development Officer - 2020
Jacqueline Miller, Dr. Senior VP-Infectious Disease Development - 2020
Members of the board
Name Title Age Since
Noubar Afeyan Chairman 58 2012
Paul Sagan Independent Non-Executive Director 62 2018
Robert Langer Independent Non-Executive Director 73 2010
Stephen A. Berenson Independent Non-Executive Director 60 2017
Francois Nader Independent Non-Executive Director 64 2019
Sandra J. Horning, Dr. Independent Director 72 2020
Elizabeth E. Tallett Independent Director 71 2020
Elizabeth G. Nabel, Dr. Independent Director 69 2021
Stéphane Bancel Chief Executive Officer & Director 48 2011
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 397,759,517 360,280,736 90.6% 0 0.0% 90.6%
Shareholders
NameEquities%
Baillie Gifford & Co. 45,629,226 11.5%
The Vanguard Group, Inc. 25,612,184 6.44%
Stéphane Bancel 21,307,198 5.36%
Flagship Pioneering 17,281,016 4.34%
SSgA Funds Management, Inc. 14,847,130 3.73%
Robert Langer 11,510,060 2.89%
BlackRock Fund Advisors 7,472,252 1.88%
Coatue Management LLC 6,928,147 1.74%
Geode Capital Management LLC 6,436,354 1.62%
Thélème Partners LLP 6,336,940 1.59%
Markets and indexes
- Nasdaq Global Select Market
- Nasdaq 100 / S&P 500, Stoxx Americas 100
Stock Exchange Codes
- Bloomberg Code :  
- Reuters Code :  MRNA.O
- Datastream Code :  
Company contact information
Moderna, Inc.
200 Square Technology
MA 02139 Cambridge, Massachusetts

Phone : +1 617 714 6500
Fax : +1 617 583 1998
web site : https://investors.modernatx.com/
Brand Portfolio
In partnership withAllbrands.markets
More brands of Moderna, Inc.